Screening and prioritizing hazardous substances in groundwater is crucial to monitor and control groundwater quality. Total of 283 substances were determined in 213 groundwater samples from the Beijing-Tianjin-Hebei region during 2019-2020. 184 substances were screened as candidates. 22 prioritizing indicators were evaluated and scored for the candidates to reflect their occurrence, mobility, persistence, bioaccumulation, acute and chronic ecotoxicities with different trophic levels, and long-term human health effects. Multi-attribute decision-making technologies were applied to prioritize these candidates, including analytic hierarchy process (AHP), TOPSIS and VIKOR. Greater weightings in AHP were assigned to attributes of occurrence and acute toxicity by experts' judgment. Hierarchical cluster analysis and principal component analysis were used to transform initial matrix with the 22 indicators into an orthogonalized matrix with 6 principal components, which represented general toxicity to aquatic organism and mammal, bioaccumulation, carcinogenicity & mutagenicity, persistence, and teratogenicity & endocrine, respectively. VIKOR and TOPSIS results were similar, but different from the AHP ranking. Two filter criteria harmonized their difference. Twenty-three substances were proposed as the priority substance with high hazard and potential exposure, and nitrate-nitrogen and ammonia-nitrogen were selected as additional priority substance frequently and extensively exceeding official groundwater quality standard on the regional scale.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jhazmat.2021.127142 | DOI Listing |
Rare diseases are collectively common, affecting approximately one in twenty individuals worldwide. In recent years, rapid progress has been made in rare disease diagnostics due to advances in DNA sequencing, development of new computational and experimental approaches to prioritize genes and genetic variants, and increased global exchange of clinical and genetic data. However, more than half of individuals suspected to have a rare disease lack a genetic diagnosis.
View Article and Find Full Text PDFEClinicalMedicine
August 2024
Center for Intelligent Medicine Research, Greater Bay Area Institute of Precision Medicine (Guangzhou), State Key Laboratory of Genetic Engineering, Center for Evolutionary Biology, School of Life Sciences, Fudan University, Guangzhou, China.
Background: Pulmonary embolism causes a substantial burden of morbidity and mortality. Although there are several well-established risk factors for pulmonary embolism, a substantial proportion of cases cannot be attributed to provoked or known risk factors. Accumulating evidence has suggested an association of clonal hematopoiesis of indeterminate potential (CHIP) with the risk of arterial thromboembolism.
View Article and Find Full Text PDFCancer is a critical disease that affects a person physically, mentally, socially, and in many other aspects. During the treatment stage of cancer, patients suffer from various health complexities, especially elderly people, which might result in the onset of other diseases development of a comorbid condition. Several studies have shown comorbidity plays a crucial role in cancer survival.
View Article and Find Full Text PDFPrecision oncology matches tumors to targeted therapies based on the presence of actionable molecular alterations. However, most tumors lack actionable alterations, restricting treatment options to cytotoxic chemotherapies for which few data-driven prioritization strategies currently exist. Here, we report an integrated computational/experimental treatment selection approach applicable for both chemotherapies and targeted agents irrespective of actionable alterations.
View Article and Find Full Text PDFMAbs
December 2025
Department of Oncology, Novartis Biomedical Research, Cambridge, MA, USA.
P-cadherin (pCAD) and LI-cadherin (CDH17) are cell-surface proteins belonging to the cadherin superfamily that are both highly expressed in colorectal cancer. This co-expression profile presents a novel and attractive opportunity for a dual targeting approach using an antibody-drug conjugate (ADC). In this study, we used a unique avidity-driven screening approach to generate pCAD x CDH17 bispecific antibodies that selectively target cells expressing both antigens over cells expressing only pCAD or only CDH17.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!